Novel influenza antigens
AssigneeGlaxosmithkline Biologicals SA
InventorVentzislav Bojidarov VASSILEV
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel influenza antigens, novel immunogenic or vaccine compositions, as well as to uses of and to methods for producing said antigens and compositions. In particular, the invention relates to recombinant forms of hemagglutinin (HA) and their use in vaccine compositions for the prevention of influenza virus infections.
Claims21
1-27. (canceled)
A method for producing a recombinant influenza virus hemagglutinin (HA) antigen comprising the extracellular domain of HA or an immunogenic portion thereof, a hydrophobic signal and a heterologous trimerisation domain comprising expressing a polynucleotide encoding said recombinant influenza virus hemagglutinin (HA) antigen in a eukaryotic cell, such as a mammalian cell, e.g. a CHO cell, or an insect cell, optionally further comprising purifying/isolating the recombinant HA from the eukaryotic cell.
A method for prevention and/or vaccination against influenza disease, comprising the administration a recombinant influenza virus hemagglutinin (HA) antigen comprising the extracellular domain of HA or an immunogenic portion thereof, followed by a hydrophobic signal, followed by a heterologous trimerisation domain to a person in need thereof.
Dependencies are inferred from the claim text.